The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.
By R. Azziz, E. Carmina, Didier Dewailly, E. Diamanti-Kandarakis, H. Escobar-Morreale, W. Futterweit, O. Janssen, R. Legro, R. Norman, A. Taylor and 1 more. Fertility and Sterility, 2009
2,022 citations recorded by the source corpus.
Subfields: Reproductive Medicine
View Paper: https://www.semanticscholar.org/paper/c4aee463a868eebfbed8fb237fbd78f98a75565a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Reproductive Medicine
- H. Escobar-Morreale
- R. Norman
- D. Ehrmann
- E. Diamanti-Kandarakis
- D. Dumesic
- Didier Dewailly
- R. Azziz
- Ankur K. Nagaraja
Citations in the corpus
- Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. (2010, background): “With increased adiposity in two thirds of American PCOS women (8), the degree to which obesity and PCOS interact to promote premature atherosclerosis and increase cardiovascular mortality is a worldwide concern (9–14).”
- The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. (2016, background): “ther oligo-anovulation or PCOM (28); this allows a diagnosis of PCOS in women with hyperandrogenism who lack anovulatory symptoms (“ovulatory PCOS”), which comprises about 10% of cases.”
- The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. (2014, positive): “Anti-androgens " Hyperandrogenaemia/hyperandro-genism is an integral part of PCOS and an imperative criterion for the diagnosis of PCOS (4, 5, 7).”
- Polycystic ovary syndrome: etiology, pathogenesis and diagnosis (2011, background): “Pathogenesis Androgen excess Androgen excess is considered by some investigators to be the sine qua non of PCOS; however, only 80–85% of women with clinical hyperandrogenism have PCOS”
- The mammalian ovary from genesis to revelation. (2009, background): “In addition to clinical features of hyperandrogenism due to excess ovarian and adrenal androgen production, this heterogeneous disorder is accompanied by ovarian dysfunction, including ovulatory defects and/or polycystic ovaries (271).”